were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was given intravenously (i.v.) at a dose of 150 mglm' on days 1, 3 and 5 every 3 weeks. The second trial investigated a daily oral dose of 100 mg for 21 days followed by a 2-week treatment-free period, and then recycling. In both trials, the treatment was given until disease progression, intolerable toxicity or patient refusal. In the i.v. trial, 49 patients were included, 2 patients were ineligible. The oral trial recruited 45 patients, 4 patients were not eligible. In both trials, the main side-effects were moderate leucopenia, alopecia, nausea and vomiting. Two partial responses (4%) and three partial responses (7') were reported in the i.v. and oral trials, respectively. The median survival was 29 weeks and 38 weeks in the i.v. and oral trials, respectively. In conclusion, further investigation of etoposide in malignant mesothelioma is not recommended. :j, 1997 Elsevier Science Ltd.
INTRODUCTION

MALIGNANT
MEsoTHELIoMA may originate from the pleura, peritoneum, pericardium or tunica vaginalis. Apart from the rare and early localised forms, this tumour is unresectable and most patients die within 1 year after diagnosis. Since the first description of mesothelioma in the early 193Os, the incidence based on tumour registries has steadily increased and is expected to continue to rise in the next decade [ 11.
Published estimates for incidence in Europe are rare. In the Nantes-Saint Nazaire region, France, the incidence during the period 19851992 was 10.9 per million inhabitants ver-sus 8.7 for the period 19751984 and 2.6 for the period [1956] [1957] [1958] [1959] [1960] [1961] [1962] [1963] [1964] [1965] [1966] [1967] [1968] [1969] [1970] [1971] [1972] [1973] [1974] [2]. In Norway, the age-adjusted incidence rate for men increased from 4 per million in the period 1960-1969 to 14 per million in the period 1980-1988 [3] . In the United States the annual incidence of mesothelioma is roughly estimated to be 2200 new cases [4-61.
Despite treatment, mesothelioma remains a rapidly progressing and lethal malignancy. Various chemotherapeutic agents have been tested in mesothelioma. A recent review of phase II trials noted that no drugs have consistently induced a response rate greater than 20% [7] .
Etoposide (VP1 6-2 13), a semisynthetic podophyllotoxin derivative, is an inhibitor of DNA topoisomerase II resulting in stabilisation of DNA strand breaks [8] . Etoposide has demonstrated considerable efficacy against a broad spec-trum of tumours [9] . The drug is thought to act in the late S and early G2 phases of the cell cycle, and is highly schedule dependent [lo] . In the first trial, etoposide was given iv. at a dose of 150 mg/m2 on days 1, 3 and 5 every 3 weeks. The drug, supplied as a 100 mg solution in ampoules, was dissolved in normal saline at a maximum concentration of 0.6 mgiml. The infusion time was at least 30 min. The second trial investigated etoposide given orally at a daily dose of 100 mg capsules (Vepesid) for 21 days followed by a 2-week treatment-free period, and then recycle. In both trials, the treatment was given until disease progression, intolerable toxicity or patient refusal.
PATIENTS AND METHODS
Patient
The The median number of administered cycles was three in both trials and varied between 1 and 12 in the i.v. trial and between 1 and 7 in the oral trial. The median total dose of etoposide was 1350 mg/m2 (maximum 5400 mg/m') and 6624 mg (maximum 14 700 mg) in the i.v. and oral trials, respectively.
In the iv. trial, the dose was reduced because of myelosuppression in 3 cases, because of weight loss in 1 patient and because of dyspnoea in another patient. Delays were reported in 8 patients: 3 due to haematological toxicity, and 5 for reasons unrelated to toxicity. In the oral etoposide trial, dose reduction was documented in 3 patients: one because of poor general conditions and treatment-unrelated in 2 other patients. Treatment delays were reported for 5 patients in the oral etoposide trial: 2 due to haematological toxicity and 3 were considered unrelated to treatment. In the i.v. trial, two early deaths were reported. One patient died 2 weeks after starting the treatment due to rapidly progressing disease, with no substantial toxicity. Another patient died at home 2 weeks after the start of the first cycle. During this cycle, no severe toxicity was reported. No autopsy was performed and a precise cause of death could not be established.
The most common side-effects were leucopenia, nausea, vomiting and alopecia (Table 2 ). In the i.v. trial, the median nadir values for leucocytes and platelets were 3.5 x IO911 (range 0.5-9.0) and 255 x lo911 (range 119- with 6% and 0% grade 3-4 toxicity, respectively. In the oral trial, the median nadir values for leucocytes and platelets were 4.0 x lo911 (range 0.9-12.6) and 274 x 109/1 (range 24-778), with 12% and 2% grade 3-4 toxicity, respectively. Hair loss was complete in 17% and 24% in the i.v. and oral trials, respectively. Nausea and vomiting were observed in 55% (grade 3-4 in 4%) and 66% (grade 3-4 in 10%) of the patients in the i.v. and oral trials, respectively. Drug fever was reported in a total of 7 patients; 2 in the i.v. trial and 5 in the oral trial. Mucositis, local phlebitis, diarrhoea and allergy were observed infrequently and were not severe.
In the i.v. trial, partial responses were documented in 2 patients (4%, 95% exact confidence interval: l-15%). Stable disease was observed in 15 patients and 25 patients progressed on treatment. 2 patients died after only one cycle (see above). The response was not assessable in 3 other patients because they had received only one cycle: due to poor performance status in 1 patient, hypotension and pulmonary oedema (possibly due to cardiac toxicity) in another patient, and the third patient suffered from severe anaphylactic reaction (dyspnoea and bronchial spasm 2 min after the first infusion). One response lasted for 32 weeks and the other patient was lost to follow-up after 28 weeks with no progression. The median survival for all eligible patients was 29 weeks (Figure 1 ).
In the oral etoposide trial, 3 patients achieved partial response (7%, 95% exact confidence interval: 2-20%), 14 patients had stable disease, 22 progressed on treatment, 1 patient died after one cycle due to malignant disease and the response could not be evaluated in another patient, who received only one cycle due to severe thrombocytopenia leading to a haemorrhage. The three partial responses lasted 
(2) (0)
(2) for 26, 30 and 52 weeks. The median survival for eligible patients was 37 weeks (Figure 1) . DISCUSSION Both trials demonstrate a low activity of etoposide in mesothelioma when given iv. for three alternative days or with chronic oral route. We could not prove any advantage of giving oral etoposide for a prolonged period. Oral etoposide is known to yield a considerable intrapatient and interpatient variation in drug bioavailability [25] . Assuming a 40-50% oral bioavailability, the average actually delivered total dose in the oral etoposide trial was roughly equivalent to that in the i.v. trial (6624 mg and 1350 mgim', respectively) . Toxicity in general was similar for the two different routes of administration.
However, the relatively modest leucopenia, especially in the oral route trial, could be partially explained by the protocol requirement for haematological evaluation.
In the i.v. trial, blood cell counts were required weekly during the first two cycles and were thereafter mandatory only prior to starting the next cycle. In the oral trial, a complete blood count was required only at days 22, 29 and 36 of each cycle.
The accrual of both trials was higher than initially planned, because some partial responses were not subsequently confirmed by the study coordinator. These unconfirmed responses led to the continuation of recruitment to over 40 patients in both trials, in accordance with the study design.
We observed a difference in survival in favour of the oral route. However, one should not overinterpret the apparent difference in the duration of survival because of the lack of randomisation, and because of the poor activity of the treatment. This difference could be simply due to an imbalance in some prognostic factors such as sex (4% females in the i.v. trial versus 15% in the oral trial) or having a purely sarcomatous histological subtype (50% in the i.v. trial versus 21% in the oral trial).
Because etoposide combined with cisplatin has been shown to be synergistic in animal models [26] and has proven efficacious in other tumours, two studies investigated this combination in malignant pleural mesothelioma. This combination gave only three partial responses in 27 eligible patients (11%) in a Canadian study [27] . In another small study of 25 patients, oral etoposide for 15 days was associated with high-dose weekly cisplatin [28] ; a response rate of 24% (one complete response and five partial responses) was observed.
This somewhat encouraging result may well be explained by the intensive cisplatin dosing but because of the small number of patients enrolled, the confidence intervals of this study are rather large.
In conclusion, we do not think that further investigation of etoposide alone in mesothelioma is to be recommended in the dose and schedule administered in our two studies.
